Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Mar;125(3):333-9.
doi: 10.1001/archopht.125.3.333.

Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians

William G Christen  1 , Joann E Manson, Robert J Glynn, J Michael Gaziano, Emily Y Chew, Julie E Buring, Charles H Hennekens
Affiliations
Randomized Controlled Trial

Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians

William G Christen et al. Arch Ophthalmol. 2007 Mar.

Abstract

Objective: To test whether beta carotene supplementation affects the incidence of age-related maculopathy (ARM) in a large-scale randomized trial.

Design: Randomized, double-masked, placebo-controlled trial among 22 071 apparently healthy US male physicians aged 40 to 84 years. Participants were randomly assigned to receive beta carotene (50 mg every other day) or placebo. Main Outcome Measure Incident ARM responsible for a reduction in best-corrected visual acuity to 20/30 or worse.

Results: After 12 years of treatment and follow-up, there were 162 cases of ARM in the beta carotene group vs 170 cases in the placebo group (relative risk [RR], 0.96; 95% confidence interval [CI], 0.78-1.20). The results were similar for the secondary end points of ARM with or without vision loss (275 vs 274 cases; RR, 1.01; 95% CI, 0.86-1.20) and advanced ARM (63 vs 66 cases; RR, 0.97; 95% CI, 0.69-1.37).

Conclusions: These randomized data relative to 12 years of treatment among a large population of apparently healthy men indicate that beta carotene supplementation has no beneficial or harmful effect on the incidence of ARM. Long-term supplemental use of beta carotene neither decreases nor increases the risk of ARM.

Trial registration: ClinicalTrials.gov NCT00000152.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incident rates of ARM.
See this image and copyright information in PMC

References

    1. National Advisory Eye Council. Bethesda, Maryland: 2004. National Plan for Eye and Vision Research. NIH Publication No. 04–4288.
    1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study Ophthalmology. 1992;99:933–943. - PubMed
    1. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials Arch Ophthalmol. 1991;109:1109–1114. - PubMed
    1. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials Arch Ophthalmol. 1993;111:1200–1209. - PubMed
    1. Bressler NM Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198–207. - PubMed

Publication types

Associated data